Browsing by Author "Bilge, N"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    The role of oligoclonal band count and IgG index in treatment response and disease activity in multiple sclerosis
    Taskiran, E; Terzi, M; Helvaci, EM; Eser, MZ; Avci, B; Faruk, TO; Yetkin, MF; Çilingir, V; Bir, LS; Kabay, SC; Bilge, N; Poyraz, T; Demir, CF; Dündar, DK; Ocak,Ö; Çam, M; Mavioglu, H; Altun, Y; Karaibrahimoglu, A
    Background/aim: Multiple sclerosis (MS) is an inflammatory demyelinating central nervous system (CNS) disease. Among the paraclinical tests, brain and spinal Magnetic Resonance Imaging (MRI) is primarily involved in the diagnosis process, and cerebrospinal fluid (CSF) analysis is fundamental in diagnosing MS and the differential diagnosis. A positive relationship was demonstrated between oligoclonal band (OCB) positivity, CSF band number and immunoglobulin G(IgG) index. The study aimed to evaluate whether the number of OCB can predict disease activity and determine a correlation with the IgG index. Methods: Our study included 401 MS patients who had relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS), clinic isolated syndrome (CIS), radiologic isolated syndrome (RIS), Neuromyelitis optica spectrum disorder (NMOSD) and Acute disseminated encephalomyelitis (ADEM) with OCB number groups of 2-4, 4-8, 8-12, and 12 and above. Results: No significant correlation was observed between IgG index, pre-and post-treatment EDSS (Expanded Disability Status Scale Scores) and disease-modifying therapies (DMT). Drug response was better in the patient group with band number between 2 and 8 and post-treatment EDSS scores were lower (1.62 +/- 0.44). Conclusion: The study results suggested that band number may be as valuable as the IgG index and a predictive biomarker for disease activity.
  • No Thumbnail Available
    Item
    The role of oligoclonal band count and IgG index in treatment response and disease activity in multiple sclerosis (vol 83,105391,2024)
    Taskiran, E; Terzi, M; Helvaci, EM; Eser, MZ; Avci, B; Faruk, TO; Yetkin, MF; Cilingir, V; Bir, LS; Kabay, SC; Bilge, N; Poyraz, T; Demir, CF; Dündar, DK; Deveci, EE; Cam, M; Mavioglu, H; Altun, Y; Karaibrahimoglu, A
  • No Thumbnail Available
    Item
    Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein
    Koç, S; Sen, S; Terzi, Y; Kizilay, F; Demir, S; Aksoy, DB; Kurtulus, F; Bilge, N; Idilman, E; Uzunköprü, C; Güngör, S; Çilingir, V; Ethemoglu,Ö; Boz, C; Gümüs, H; Kiliç, AK; Kisabay, A; Bir, LS; Turan, ÖF; Soysal, A; Köseoglu, M; Uzuner, GT; Bayindir, H; Kabay, SC; Çam, M; Yayla, V; Tan, HY; Özcan, A; Taskapioglu,Ö; Korkmaz, M; Tamam, Y; Inanç, Y; Efendi, H; Kotan, D; Yetkin, MF; Bilgiç, AB; Saçmaci, H; Demirci, S; Çelik, Y; Poyraz, T; Terzi, M
    Background: Optic neuritis, myelitis, and neuromyelitis optica spectrum disorder (NMOSD) have been associated with antibodies against myelin oligodendrocyte glycoprotein-immunoglobulin G (anti-MOG-IgG). Furthermore, patients with radiological and demographic features atypical for multiple sclerosis (MS) with optic neuritis and myelitis also demonstrate antibodies against aquaporin-4 and anti-MOG-IgG. However, data on the diagnosis, treatment, follow-up, and prognosis in patients with anti-MOG-IgG are limited. Aims: To evaluate the clinical, radiological, and demographic characteristics of patients with anti-MOG-IgG. Study Design: Multicenter, retrospective, observational study. Methods: Patients with blood samples demonstrating anti-MOG-IgG that had been evaluated at the Neuroimmunology laboratory at Ondokuz May & imath;s University's Faculty of Medicine were included in the study. Results: Of the 104 patients with anti-MOG-IgG, 56.7% were women and43.3% were men. Approximately 2.4% of the patients were diagnosed with MS, 15.8% with acute disseminated encephalomyelitis (ADEM), 39.4% with NMOSD, 31.3% with isolated optic neuritis, and 11.1% with isolated myelitis. Approximately 53.1% of patients with spinal involvement at clinical onset demonstrated a clinical course of NMOSD. Thereafter, 8.8% of these patients demonstrated a clinical course similar to MS and ADEM, and 28.1% demonstrated a clinical course of isolated myelitis. The response to acute attack treatment was lower and the disability was higher in patients aged > 40 years than patients aged < 40 years at clinical onset. Oligoclonal band was detected in 15.5% of the patients. Conclusion: For patients with NMOSD and without anti-NMO antibodies, the diagnosis is supported by the presence of anti-MOG-IgG. Furthermore, advanced age at clinical onset, Expanded Disability Status Scale (EDSS) score at clinical onset, spinal cord involvement, and number of attacks may be negative prognostic factors in patients with anti-MOG-IgG.